Recurrent Gastric Carcinoma: Clinical Trials

8 trials for Recurrent Gastric Carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 active not recruiting, 1 terminated. 6 Phase 2, 2 Phase 1, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Completed 4, Active not recruiting 2
Phase 12Completed 2
Early Phase 11Terminated 1

Follow Recurrent Gastric Carcinoma: new trials by email Literature Review of Recurrent Gastric Carcinoma trials Research Report on Recurrent Gastric Carcinoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Phase 2Active not recruitingNational Cancer Institute (NCI)292021-04-262026-11-18
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients
Cisplatin, Cytoreductive Surgery, Doxorubicin - Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm
Early Phase 1TerminatedMayo Clinic22019-11-082025-02-20
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
Olaparib, Ramucirumab - Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)512018-02-062026-02-03
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
Epacadostat, Pembrolizumab - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Phase 2CompletedGeorge Albert Fisher32017-09-132024-01-23
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)64522015-08-172026-11-12
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Phase 1CompletedRoswell Park Cancer Institute182012-03-012016-10-04
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Akt Inhibitor MK2206 - Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma
Phase 2CompletedNational Cancer Institute (NCI)752011-01-012016-01-18
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
Laboratory Biomarker Analysis, Oxaliplatin, Pralatrexate - Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma
Phase 2CompletedRoswell Park Cancer Institute352010-09-012017-12-13

Narrower conditions

Stomach Neoplasms (8)  ·  Esophageal Neoplasms (4)  ·  Ovarian Neoplasms (4)  ·  Breast Neoplasms (3)  ·  Prostatic Neoplasms (3)  ·  Carcinoma, Hepatocellular (2)  ·  Carcinoma, Renal Cell (2)  ·  Colonic Neoplasms (2)  ·  Colorectal Neoplasms (2)  ·  Lung Neoplasms (2)  ·  Melanoma (2)  ·  Pancreatic Neoplasms (2)  ·  Rectal Neoplasms (2)  ·  Sarcoma (2)  ·  Urinary Bladder Neoplasms (2)

Broader conditions

Digestive System Diseases (8)  ·  Digestive System Neoplasms (8)  ·  Gastrointestinal Diseases (8)  ·  Gastrointestinal Neoplasms (8)  ·  Neoplasms (8)  ·  Neoplasms by Site (8)  ·  Stomach Diseases (8)  ·  Esophageal Diseases (5)  ·  Head and Neck Neoplasms (5)  ·  Adnexal Diseases (4)  ·  Endocrine Gland Neoplasms (4)  ·  Endocrine System Diseases (4)  ·  Female Urogenital Diseases (4)  ·  Female Urogenital Diseases and Pregnancy Complications (4)  ·  Genital Diseases (4)

Interventions

Magnetic Resonance Spectroscopy (3)  ·  Specimen Handling (3)  ·  Biopsy (2)  ·  X-Rays (2)  ·  1,2-diaminocyclohexaneplatinum II citrate (1)  ·  10-propargyl-10-deazaaminopterin (1)  ·  2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1)  ·  2C4 antibody (1)  ·  AZD4547 (1)  ·  Ado-Trastuzumab Emtansine (1)  ·  Afatinib (1)  ·  CT-P6 (1)  ·  Cisplatin (1)  ·  Crizotinib (1)  ·  Cytoreduction Surgical Procedures (1)

Sponsors

National Cancer Institute (NCI) (4)  ·  Roswell Park Cancer Institute (2)  ·  George Albert Fisher (1)  ·  Mayo Clinic (1)

Countries

United States (8)  ·  Canada (1)  ·  Guam (1)  ·  Puerto Rico (1)

Top investigators

A P Chen (1)  ·  George A Fisher, MD (1)  ·  Keith T Flaherty (1)  ·  Kunle Odunsi (1)  ·  Michael Cecchini (1)  ·  Nikhil Khushalani (1)  ·  Patricio C. Gargollo, M.D. (1)  ·  Ramesh Ramanathan (1)

Results publications

PMID 25827820, PMID 26586415, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40132910, PMID 40865033, PMID 41066729

NIH funding

P30CA016056 (2), R01CA158318 (1), U10CA032102 (1), U10CA180820 (1), U10CA180888 (1), U24CA196172 (1), UM1CA186689 (1)